Apalutamide With ADT Maintains OS Benefit in mCSPC
February 13th 2021Apalutamide in combination with androgen deprivation therapy led to a reduction in the risk of death of 35% in comparison with ADT alone for patients with metastatic castration-sensitive prostate cancer in a final analysis of the phase 3 TITAN trial.
Read More
Adjuvant Nivolumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma
February 13th 2021Results from the phase 3 CheckMate-274 trial showed that nivolumab following surgery improved disease-free survival compared with placebo for patients with muscle-invasive urothelial carcinoma, according a presentation given during the 2021 ASCO Genitourinary Cancer Symposium.
Read More
Benefit of Enfortumab Vedotin in Previously Treated Urothelial Carcinoma Confirmed in Phase 3 Trial
February 13th 2021Enfortumab vedotin demonstrated superior efficacy compared with chemotherapy in patients with advanced urothelial carcinoma who had previously received platinum-based chemotherapy and PD-1/L1 inhibition, according to results from a primary analysis of the phase 3 EV-301 clinical trial.
Read More
Response rates to enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors were the highest numerically observed for any regimen, according to findings from study EV-201 presented at the 2021 American Society of Clinical Oncology Genitourinary Cancer Symposium.
Read More
Staging of Nonmetastatic Relapsed Prostate Cancer May Be Aided by PSMA-Directed PET Tracer
February 12th 2021A novel prostate-specific membrane antigen–targeted radiopharmaceutical for positron emission tomography known as 18F-DCFPyL, may help to identify occult prostate cancer and more accurately characterize disease burden, according to a subanalysis of the OSPREY trial presented during the 2021 Genitourinary Cancers Symposium.
Read More
In ARAMIS Trial, Crossover Has Minimal Impact on Darolutamide OS Benefit
February 12th 2021In patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), crossover from placebo to darolutamide (Nubeqa) appeared have minimal impact on the overall survival (OS) benefit observed with the androgen receptor inhibitor in the pivotal phase 3 ARAMIS trial.
Read More
TIVO-3 Trial End Point Q-TWiST Increased With Tivozanib in RCC
February 12th 2021The VEGF tyrosine kinase inhibitor tivozanib hydrochloride demonstrated a significantly increased quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy in patients with metastatic renal cell carcinoma compared with sorafenib in the phase 3 TIVO-3 trial.
Read More
Ruxolitinib Exceeds Response, Survival, and Symptom Burden End Points in Chronic GVHD
February 12th 2021Results from the phase 3, randomized REACH3 trial further demonstrated the benefit of ruxolitinib over BAT in rates for failure-free survival, symptom improvement, and duration of response.
Read More
Orca-T Achieves Impressive Outcomes in Hematologic Malignancies
February 11th 2021Data presented during the 2021 Transplantation and Cellular Therapy Meeting showed that treatment with Orca-T, achieved a significant reduction in cases of graft-versus-host disease and other impressive outcomes.
Read More
OS Benefit Suggested for Frontline IO Versus TKIs in Metastatic Non–Clear Cell RCC
February 11th 2021A retrospective study has suggested that immunotherapy may have a great survival benefit in the frontline setting for patients with metastatic non–clear cell renal cell carcinoma (RCC) than select targeted therapies.
Read More
Apalutamide/Abiraterone Extends rPFS in Metastatic Castration-Resistant Prostate Cancer
February 11th 2021In the phase 3 ACIS study, the addition of apalutamide to abiraterone acetate lead to a reduction in the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.
Read More
Japanese Patients With Urothelial Cancer Benefit From Frontline Avelumab Maintenance Addition
February 11th 2021A subgroup analysis from the phase 3 JAVELIN Bladder 100 trial demonstrated that Japanese patients with advanced urothelial cancer whose disease did not progress on frontline chemotherapy benefited from the addition of avelumab to best supportive care in the first-line maintenance setting.
Read More
Adding Eganelisib to Nivolumab May Improve Response in Metastatic Urothelial Cancer
February 11th 2021Response rates in patients with metastatic urothelial carcinoma were boosted when the novel PI3K-y inhibitor eganelisib was added to nivolumab, according to recent research presented during the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium.
Read More
Lenvatinib Plus Everolimus Signals Efficacy After Immunotherapy in ccRCC
February 11th 2021In patients with clear cell renal cell carcinoma who had been treated with an immune checkpoint inhibitor in prior lines of therapy, lenvatinib in combination with everolimus was found to be safe and effective.
Read More
Iomab-B Conditioning Therapy Leads to Successful HCT in Active AML
February 11th 2021Targeted radioimmunotherapy to the marrow with apamistamab conditioning therapy led to high rates of allogeneic hematopoietic stem cell transplant in patients with active, relapsed, or refractory acute myeloid leukemia, according to interim data from the phase 3 SIERRA trial.
Read More
Beti-Cel Shows Good Activity in Transfusion-Dependent Children With Beta-Thalassemia
February 10th 2021Results from 2 phase 3 clinical trials showed that use of the investigational gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients under the age of 18 years with transfusion-dependent beta-thalassemia.
Read More
JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS
February 9th 2021A phase 1 study is the first to demonstrate that JSP191 is safe and effective in older patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.
Read More
Narsoplimab Demonstrates Clinical Activity in High-Risk HSCT-TMA
February 9th 2021In a pivotal phase 2 trial, administration of narsoplimab to patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy led to impressive responses and a favorable survival benefit.
Read More
Stem Cells Achieve Potent Immunity Against SARS-CoV2 and Common Human Coronaviruses In Patients
February 8th 2021Finding presented on patients with hematologic malignancies at the 2021 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR show that patients who had undergone a hematopoietic stem cell transplantation can accumulate effective immunity against SARS-CoV2 infection and non-SARS human coronaviruses.
Read More
Repotrectinib Demonstrates Early Clinical Activity in ROS1+ Metastatic NSCLC
January 31st 2021Treatment with the next-generation ROS1 and TRK tyrosine kinase inhibitor repotrectinib is sustaining good objective responses and is tolerable in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated preliminary results from the phase 2 expansion 1 cohort of the ongoing phase 1/2 TRIDENT-1 clinical trial.
Read More